Evidence map›Paper›PMID 38296800›Full record

ArticleRMD open2024

Impact of biological therapy in reducing the risk of arthritis development in inflammatory bowel diseases.

Mauro Fatica, Benedetta Monosi, Paola Conigliaro, Arianna D'Antonio, Sara Essofi, Elisa Cuccagna, Alberto Bergamini, Livia Biancone, Giovanni Monteleone, Paola Triggianese and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RMD open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
5.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Mauro Fatica *Rheumatology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Benedetta Monosi *Rheumatology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Paola ConigliaroRheumatology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.ORCID 0000-0001-7905-8413
Arianna D'AntonioRheumatology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Sara EssofiGastrointestinal Unit, Departement of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Elisa CuccagnaGastrointestinal Unit, Departement of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Alberto BergaminiRheumatology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Livia BianconeGastrointestinal Unit, Departement of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Giovanni MonteleoneGastrointestinal Unit, Departement of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Paola TriggianeseRheumatology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Emma CalabreseGastrointestinal Unit, Departement of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Maria Sole ChimentiRheumatology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy maria.sole.chimenti@uniroma2.it.ORCID 0000-0002-1343-1729
University of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveEvaluate spondyloarthritis (SpA) incidence in inflammatory bowel diseases (IBD) between patients treated with biological disease-modifying antirheumatic drugs (bDMARDs) and conventional DMARDs (cDMARDs) and define risk factors associated with SpA development.

methodsRetrospective cohort study was conducted on patients with Crohn's disease (CD) or ulcerative colitis (UC) and divided into two cohorts: cDMARDs or bDMARDs/targeted synthetic (ts) DMARDs treated patients. Rheumatological assessment was performed in patients presenting musculoskeletal symptoms. Multivariate analysis and Kaplan-Meier curves were used to evaluate the adjusted SpA risk development.

results507 patients were included in the study. 176 patients with CD received bDMARDs, 112 cDMARDs and 106 new SpA diagnosies were formulated. Females (OR 1.7 (95% CI 1.1 to 3), adjusted p=0.04), non-stricturing/non-penetrating phenotype (OR 2 (95% CI 1.1 to 3.4), adjusted p=0.01), psoriasis (OR 2.1 (95% CI 1 to 4.6), adjusted p=0.04) and non-infectious uveitis (OR 6.8 (95% CI 1.4 to 33.4), adjusted p=0.01) were associated with increased SpA risk development, while bDMARDs usage was protective (OR 0.4 (95% CI 0.2 to 0.8), adjusted p=0.01), statistically higher than cDMARDs throughout the entire follow-up (effect size 0.47). 98 patients with UC received b-tsDMARDs, 121 cDMARDs and 56 new SpA diagnoses were formulated. Females (OR 2.1 (95% CI 1 to 4.3), adjusted p=0.02) and psoriasis (OR 2.7 (95% CI 1 to 6.8), adjusted p=0.03) were associated with increased SpA risk development, while bDMARDs were protective for SpA development for up to 12 months of treatment compared with cDMARDs (p=0.03).

conclusionsbDMARDs treatment had an impact in reducing SpA development and clinical associated risk factors to transition from IBD to IBD-SpA emerged.

Indexed as

Antirheumatic AgentsInflammatory Bowel DiseasesPsoriasisSpondylarthritisBiological TherapyFemaleHumansRetrospective StudiesAntirheumatic AgentsBiological TherapyImmune System DiseasesInflammatory Bowel DiseasesSpondyloarthritis

Identifiers

PMID38296800
PMCPMC10831466
OpenAlexW4391444989

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.